1. Volume 8, Issue 12, Pages 1071-1078 (December 2007)
RETRACTED: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG clinical trial 
Prof Hervé Bonnefoi, MD, Anil Potti, MD, Mauro Delorenzi, PhD, Louis Mauriac, MD, Mario Campone, MD, Michèle Tubiana-Hulin, MD, Prof Thierry Petit, MD, Philippe Rouanet, MD, Prof Jacek Jassem, MD, Emmanuel Blot, MD, Véronique Becette, MD, Pierre Farmer, PhD, Sylvie André, Chaitanya R Acharya, MS, Sayan Mukherjee, PhD, Prof David Cameron, MD, Prof Jonas Bergh, MD, Prof Joseph R Nevins, PhD, Prof Richard D Iggo, PhD 
The Lancet Oncology 
Volume 8, Issue 12, Pages (December 2007)
DOI: /S (07)
Copyright © 2007 Elsevier Ltd Terms and Conditions

2. Figure 1 Study design of EORTC 10994/BIG 00-01 trial
FEC=fluorouracil, epirubicin, and cyclophosphamide. T=docetaxel. ET=epirubicin plus docetaxel. *Surgery was followed by radiotherapy or hormonal therapy (or both) according to each centre's policy.
The Lancet Oncology 2007 8, DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

3. Figure 2
Prediction of pathological complete response with genomic signatures stratified by trial group
pCR=pathological complete response. Each point is an individual patient. Triangles=pathological complete response. Circles=no pathological complete response. Green=patient received FEC. Blue=patient received TET. Green dashed lines show the mean values in each group. Black dashed lines show maximum empirical Youden index; those in the upper-left and lower-right panels were used to calculate the performance metrics in table 2.
The Lancet Oncology 2007 8, DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

4. Figure 3
ROC analysis of the ability of genomic signatures to discriminate patients with a pathological complete response from patients with residual disease
AUC, number of cases (N), and location of the maximum empirical Youden index (green point) are shown.
The Lancet Oncology 2007 8, DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

5. Figure 4
Predicted probabilities of pathological complete response to FEC and TET treatments
pCR=pathological complete response. Each point corresponds to an individual patient. Plot shows predicted probabilities of pCR calculated from microarray data (the recorded values, as shown in figure 2). The vertical and horizontal dotted lines are drawn at the thresholds used to calculate the performance metrics in table 2. The treatment allocation model assigns patients to FEC when points are above the diagonal line and to TET when below it. The point marked by an arrow is discussed in the text.
The Lancet Oncology 2007 8, DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

6. Figure 5 Treatment allocation model
pCR=pathological complete response. The red line shows how the hypothetical pathological complete response rate changes as the proportion of patients allocated to each treatment changes.
The Lancet Oncology 2007 8, DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions